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Short Communication
Integrin avb6-associated ERK2 mediates MMP-9 secretion in colon
cancer cells
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There is general consensus that matrix metalloproteinases are involved in tumour progression. We show herein that inhibition
of integrin avb6 expression in colon cancer cells suppresses MMP-9 secretion. This integrin-mediated event is dependent upon
direct binding between the b6 integrin subunit and extracellular signal-regulated kinase 2. Targetting either b6 or its interaction
with extracellular signal-regulated kinase in order to inhibit matrix metalloproteinase activity may offer a useful therapeutic
approach in preventing growth and spread of colon cancer.
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Tumour progression reﬂects the ability of cancer cells to proliferate
and invade surrounding matrix barriers and these events are regu-
lated, at least in part, by cell adhesion receptors called integrins and
matrix-degrading enzymes. Integrins consist of alpha (a) and beta
(b) subunit molecules in close non-covalent association that form
structural and functional bridges between the extracellular matrix
and cytoskeletal proteins within a cell (Hynes, 1992). Within the
av integrin subfamily, avb6 is not expressed in normal epithelia;
however, it becomes highly expressed during tumorigenesis and
the b6 integrin subunit is thought to be widespread in cancers of
the lung, breast, pancreas, ovary, oropharynx and colon as well
as in the tracheal airway epithelium of heavy smokers (Sheppard
et al, 1990; Breuss et al, 1995; Agrez et al, 1996; Thomas et al,
1997; Arihiro et al, 2000). Heterologous expression of avb6i na
colon cancer cell line that lacks constitutive avb6 expression has
been shown by us to enhance tumour growth in vitro and in vivo
thought to be due, in part, to avb6-mediated matrix metalloprotei-
nase-9 (MMP-9) secretion (Agrez et al, 1994, 1999; Niu et al,
1998). Furthermore, we have reported that avb6 induces its own
expression in an autocrine manner with cell crowding and
proposed a self-perpetuating model of colon cancer progression
regulated through avb6-mediated MMP-9 secretion (Niu et al,
2001).
The importance of the mitogen-activated protein (MAP) kinase
signalling pathway in promoting cancer growth in vivo is now no
longer in question. In a recent breakthrough in this ﬁeld, a highly
potent inhibitor of MAP kinase activation has been identiﬁed
which is capable of inhibiting human cancer growth in immune-
deﬁcient mice (Sebolt-Leopold et al, 1999). We have recently
demonstrated a direct physical interaction between avb6 and a
member of the MAP kinase family, extracellular signal-regulated
kinase 2 (ERK2) which deﬁnes a novel paradigm of integrin-
mediated signalling in cancer (Ahmed et al, 2002). Moreover, we
have shown that suppression of either wild-type b6 expression or
expression of b6 deﬁcient in the binding domain for ERK2 drama-
tically inhibits colon cancer cell growth (Ahmed et al, 2002). In the
present study we describe the effect of either down-regulation of b6
expression or loss of the binding site on b6 for ERK2 on MMP-9
secretion.
MATERIALS AND METHODS
Cell lines and culture conditions
The human colon cancer cell lines WiDr and HT29 were obtained
from the American Type Culture Collection (ATCC; Rockville,
MD, USA) and maintained as monolayers in standard medium
comprising Dulbecco’s Modiﬁed Eagles Medium (DMEM;
4.5 g l
71 glucose) with 10% heat-inactivated foetal bovine serum
(FBS) supplemented with HEPES and penicillin/streptomycin. Both
cell lines were transfected with the b6 gene construct in antisense
orientation and stable transfectants selected continuously in puro-
mycin (WiDr, 1 mgm l
71; HT29, 2.5 mgm l
71) as previously
described (Ahmed et al, 2002). Cells transfected with the expression
plasmid only were established as controls (mock transfectants).
Stably transfected SW480 colon cancer cells (ATCC) expressing
either wild-type b6o rb6 cytoplasmic domain deletion mutant
lacking the ERK2 binding site were prepared as previously
described (Agrez et al, 1994; Cone et al, 1994). SW480 cells trans-
fected with the expression plasmid only (mock transfectants) were
prepared as controls (Agrez et al, 1994).
Tumour-conditioned medium (TCM) for MMP-9 estimation
was prepared by removal of FBS-containing medium and three
washes of the adherent cells with phosphate-buffered saline before
addition of chemically deﬁned serum-free medium. Serum-free
medium comprised DMEM (minus phenolphthalein) supplemen-
ted with ITS (insulin, selenous acid and transferrin), HEPES and
penicillin/streptomycin and was harvested 48 h later. In some
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San Diego, CA, USA) was added to the serum-free cultures. The
TCM was cleared of cells and debris by centrifugation at 3290 g
for 10 min, followed by protein estimation using the BCA protein
assay reagent (Pierce, Rockford, IL, USA) to ensure equivalent
loading onto zymogram gels.
Zymography
MMP-9 was analysed in SDS-substrate gels by adding gelatin
(0.1 mg ml
71 ﬁnal concentration) to the 10% acrylamide separat-
ing gel. TCM collected under serum-free conditions was mixed
with substrate gel sample buffer (10% SDS, 50% glycerol, 25 mM
Tris-HCI (pH 6.8) and 0.1% bromophenol blue), and 70 ml loaded
onto the gel without prior boiling. Following electrophoresis, gels
were washed twice in 2.5% Triton X-100 for 30 min at room
temperature to remove the SDS. Gels were then incubated at
378C overnight in substrate buffer containing 50 mM Tris HCl
and 5 mM CaCl2 (pH 8.0). Gels were stained with 0.15% Coomas-
sie blue R250 in 50% methanol, 10% glacial acetic acid for 20 min
at room temperature and de-stained in the same solution without
Coomassie blue. Gelatin-degrading enzymes were identiﬁed as clear
bands against the blue background of stained gel.
MMP-9 activity assay
MMP-9 levels in TCM obtained from antisense b6 transfectants
were assayed using a commercially available kit, the Biotrak
MMP-9 activity assay system (Amersham, Aylesbury, UK). This
assay measures total MMP-9 levels (inactive pro-enzyme activated
artiﬁcially plus endogenous active enzyme forms) and MMP-9
secretion is calculated on a per-cell basis.
RESULTS
Suppression of b6-expression, MEK inhibition, or deletion
of the b6-ERK2 binding site inhibits MMP-9 secretion
The inhibitory effect of down-regulation of b6 expression on
MMP-9 secretion for the WiDr and HT29 cell lines which consti-
tutively express avb6 is shown in Figure 1A. Amounts of MMP-9
secreted per cell into serum-free tumour-conditioned medium
from both lines was 2–3-fold higher for mock transfectants,
compared with cells transfected with antisense b6 (Figure 1A).
Transfection of SW480 cells with the b6 gene construct has been
shown to markedly enhance MMP-9 secretion (Niu et al, 1998;
Agrez et al, 1999). As shown in Figure 1B, SW480 b6 transfectants
not only secrete markedly more MMP-9 into tumour-conditioned
medium than SW480 cells transfected with vector alone (mock
transfectants) but this was inhibitable by the MEK-1 inhibitor,
PD98059. Repeated estimation of MMP-9 secretion by PD98059-
treated cells using gel zymography and densitometric quantitation
for three separate experiments revealed a reduction in MMP-9
secretion of 41+8% (mean+s.e.m., data not shown). We have
recently identiﬁed the binding site on the b6 cytoplasmic domain
for ERK2 (Ahmed et al, 2002). In the present study, heterologous
expression of a b6 mutant lacking the binding site for ERK2
reduced MMP-9 secretion to levels seen for non-b6 expressing
mock transfectants as shown in Figure 1C.
DISCUSSION
Matrix degradation by MMPs is crucial for growth, invasion,
metastasis and angiogenesis of tumours and increased tissue
expression of MMP-9 has been observed in the progression from
benign to malignant colonic epithelium (Kossakowska et al,
1996). Maximal expression of MMPs has also been noted at the
invading margin of tumour cell islands as in colon cancer (Hewitt
et al, 1991) and plasma MMP levels are signiﬁcantly elevated in
patients with this disease (Zucker et al, 1995). We have previously
reported a direct positive correlation between levels of expression
of the b6-integrin subunit in SW480 colon cancer cells and
MMP-9 secretion (Agrez et al, 1999). Moreover, tumour cell prolif-
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Figure 1 Effect of b6 suppression, MEK inhibition and deletion of the
ERK2 binding site on b6 on MMP-9 secretion. (A) MMP-9 levels in tu-
mour-conditioned medium (TCM) from WiDr and HT29 mock/antisense
b6 transfectants. The data represent mean (+s.e.m.) levels of MMP-9
(ng cell
71) for three independent experiments. Asterisks denote statisti-
cally signiﬁcant differences in MMP-9 secretion levels between mock and
antisense b6 transfectants for each cell line (P50.05, Two-sample Wilcoxin
rank-sum (Mann-Whitney) test). (B) Gelatin zymogram showing gelatinase
activity in TCM from SW480 cells transfected with either the b6 gene con-
struct or with vector alone (mock transfectants). The cells had been ex-
posed to either the MEK-1 inhibitor PD98059 (50 mM) or vehicle control
(DMSO) and the position of puriﬁed MMP-9 is shown on the left. (C) Ge-
latin zymogram showing gelatinase activity in TCM from SW480 cells ex-
pressing either mutant b6 that lacks the ERK2 binding domain, wild-type
b6 or vector alone (mock transfectants). The position of puriﬁed MMP-9
is shown on the right.
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sing SW480 cells is associated with conversion of tumour cell
colonies from compact to spreading colonies and exposure of the
cells to a speciﬁc MMP inhibitor abolishes b6-mediated tumour
cell proliferation and colony spreading within a collagen matrix
(Agrez et al, 1999). These ﬁndings are consistent with the observa-
tion by Manasseh et al (1999) that transfection of a human MMP-9
vector into SW480 wild-type cells resulted in enhanced cell migra-
tion and invasion in vitro.
The role of MAP kinases in the regulation of MMP expression
in malignant cells is now well recognised. MMP-9 production
has been shown to be directly dependent on the activation of endo-
genous ERK signalling in hepatocyte growth factor- or epidermal
growth factor-stimulated human epidermal keratinocytes (Zeigler
et al, 1999). Induction of MMP-9 promoter activity by oncogenic
Ras in squamous carcinoma cells has been shown to be abrogated
by blocking the ERK 1/2 pathway (Gum et al, 1997). Increased
transcriptional activity of the MMP-9 promoter in Ras-transformed
ovarian carcinoma cells has also been shown to be mediated by
MAP kinases (Gum et al, 1996). In the present study, we show that
down-regulation of constitutive b6 expression using an antisense
approach against b6, that is known to suppress MAP kinase activity
(Ahmed et al, 2002), dramatically reduced MMP-9 levels in
tumour-conditioned medium. Inhibition of MAP kinase activity
by the MEK-1 inhibitor PD98059, also markedly reduced MMP-9
secretion in cells transfected with the b6 gene construct.
To speciﬁcally examine the role of b6-bound ERK2 on MMP-9
secretion we tested the ability of cells expressing a b6 deletion
mutant that lacks the binding site for ERK2 to secrete MMP-9 into
tumour-conditioned medium. We have previously reported that
transfection of SW480 cells with either the wild-type b6 gene
construct or a b6 construct lacking the binding domain for
ERK2 results in equivalent levels of expression of these receptors
in the respective cell lines (Ahmed et al, 2002). However, lack of
the ERK2 binding site on b6 reduced MMP-9 secretion to levels
seen for non-b6 expressing cells. This may account, at least in part,
for the reduced tumour growth in vivo observed for cells expressing
b6 that lacks the ERK2 binding site compared with cells expressing
wild-type b6 (Ahmed et al, 2002). Importantly, in cells that either
lack b6 or express b6 lacking the ERK2 binding domain, ERK2
associates with the b5 integrin subunit (Ahmed et al, 2002). While
the signiﬁcance of the b5-ERK2 binding event remains to be deter-
mined we have postulated that a hierarchy of integrin-ERK2
interactions exists within cancer cells with preferential binding of
the kinase to the growth-promoting b6 subunit when it is
expressed (Ahmed et al, 2002). It is this preferential binding event
that is responsible for enhanced MMP-9 secretion in cells when
they express avb6.
Attempts to inhibit tumour progression by blocking matrix-
degrading activity have led to the development of synthetic MMP
inhibitors that have shown promise in recent clinical trials invol-
ving cancers of the pancreas, stomach, lung and bowel
(Wojtowicz-Praga et al, 1998; Primrose et al, 1999; Rosemurgy et
al, 1999; Tierney et al 1999). However, signiﬁcant side effects from
the use of MMP inhibitors have also been documented (Wojto-
wicz-Praga et al, 1998; Hutchinson et al, 1998; Primrose et al,
1999). Given that the b6-ERK2 interaction mediates MMP-9 secre-
tion and that de novo expression of b6 occurs in epithelial cancer
cells, inhibition of MMP activity by targetting either b6 or the
ERK2 binding site may offer greater therapeutic speciﬁcity in
cancer treatment than MMP inhibitors and avoid unwanted side
effects.
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